1. Metabolic Enzyme/Protease Vitamin D Related/Nuclear Receptor
  2. Mineralocorticoid Receptor Endogenous Metabolite
  3. Eplerenone

Eplerenone  (Synonyms: 依普利酮; Epoxymexrenone)

目录号: HY-B0251 纯度: 99.81%
COA 产品使用指南

Eplerenone (Epoxymexrenone) 是一种选择性和高度特异性醛固酮阻滞剂 (SAB),具有口服活性。Eplerenone 也是一种选择性矿糖皮质激素受体拮抗剂 (MRA),其 IC50 值为 0.081 μM。Eplerenone 可用于高血压、动脉粥样硬化、慢性收缩期心力衰竭 (HF) 和心血管 (CV) 的研究。

MCE 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

Eplerenone Chemical Structure

Eplerenone Chemical Structure

CAS No. : 107724-20-9

1.  客户无需承担相应的运输费用。

2.  同一机构(单位)同一产品试用装仅限申领一次,同一机构(单位)一年内

     可免费申领三个不同产品的试用装。

3.  试用装只面向终端客户

规格 价格 是否有货 数量
10 mM * 1 mL in DMSO ¥785
In-stock
5 mg ¥446
In-stock
10 mg ¥714
In-stock
50 mg ¥1900
In-stock
100 mg ¥2450
In-stock
200 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

Customer Review

Other Forms of Eplerenone:

  • 生物活性

  • 纯度 & 产品资料

  • 参考文献

生物活性

Eplerenone (Epoxymexrenone) is a selective, highly specific and orally active aldosterone blocker (SAB). Eplerenone also is a selective mineralocorticoid receptor antagonist (MRA) with IC50 value of 0.081 μM. Eplerenone can be used for the research of hypertension, atherosclerosis, chronic systolic heart failure (HF) and cardiovascular (CV)[1][2].

IC50 & Target

IC50: 0.081 μM (human mineralocorticoid receptor) [2]

细胞效力
(Cellular Effect)
Cell Line Type Value Description References
A10 IC50
> 5000 nM
Compound: 1
Inhibition of L-type calcium channel in rat A10 cells assessed as inhibition of depolarization-induced increase in calcium flux after 48 hrs by FLIPR assay
Inhibition of L-type calcium channel in rat A10 cells assessed as inhibition of depolarization-induced increase in calcium flux after 48 hrs by FLIPR assay
[PMID: 20408553]
COS-1 IC50
1300 nM
Compound: Eplerenone
Antagonist activity at human mineralocorticoid receptor expressed in COS1 cells after 1 day by luciferase reporter gene assay
Antagonist activity at human mineralocorticoid receptor expressed in COS1 cells after 1 day by luciferase reporter gene assay
[PMID: 25187277]
COS-1 IC50
1300 nM
Compound: Eplerenone
Antagonist activity at human MR transfected in human COS1 cells after 1 day by luciferase reporter gene assay
Antagonist activity at human MR transfected in human COS1 cells after 1 day by luciferase reporter gene assay
[PMID: 22074142]
HEK293 IC50
2600 nM
Compound: Eplerenone
Displacement of [3H]aldosterone from cytosolic human MR expressed in HEK293 cells after 16 hrs by scintillation counting
Displacement of [3H]aldosterone from cytosolic human MR expressed in HEK293 cells after 16 hrs by scintillation counting
[PMID: 22074142]
Huh-7 IC50
122 nM
Compound: eplerenone
Antagonist activity at Gal4-tagged mineralocorticoid receptor expressed in human Huh7 cells by luciferase reporter gene assay
Antagonist activity at Gal4-tagged mineralocorticoid receptor expressed in human Huh7 cells by luciferase reporter gene assay
[PMID: 20672822]
Huh-7 IC50
122 nM
Compound: 1
Antagonist activity at mineralocorticoid receptor LBD expressed in human HUH7 cells coexpressing GAL4 by luciferase reporter gene assay
Antagonist activity at mineralocorticoid receptor LBD expressed in human HUH7 cells coexpressing GAL4 by luciferase reporter gene assay
[PMID: 20672820]
Huh-7 IC50
135 nM
Compound: 1
Antagonist activity at Gal4-fused mineralocorticoid receptor expressed in human HuH7 cells assessed as inhibition of aldosterone-induced receptor activation by luciferase reporter gene assay
Antagonist activity at Gal4-fused mineralocorticoid receptor expressed in human HuH7 cells assessed as inhibition of aldosterone-induced receptor activation by luciferase reporter gene assay
[PMID: 20408553]
体外研究
(In Vitro)

Eplerenone 抑制人盐皮质激素受体,IC50 值为 0.081 μM[2]

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究
(In Vivo)

Eplerenone (口服,200 mg/kg/天,持续 3 个月) 显著降低动脉粥样硬化载脂蛋白缺陷 (EO) 小鼠的氧化应激和动脉粥样硬化进展[3]

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Atherosclerotic apolipoprotein Edeficient (EO) mice[3]
Dosage: 200 mg/kg
Administration: oral, 200 mg/kg/day for 3 months
Result: Significantly decreased systolic and diastolic blood pressure by 12% and 11%, respectively.
Decreased serum susceptibility to lipid peroxidation by as much as 26%, and increased serum paraoxonase activity by 28%.
Reduced levels of lipid peroxides, and significantly reduced macrophage oxidation of low-density lipoprotein (LDL) and superoxide ion release.
Significantly reduced the atherosclerotic lesion area.
Clinical Trial
分子量

414.49

Formula

C24H30O6

CAS 号
性状

固体

颜色

White to off-white

中文名称

依普利酮

结构分类
初始来源
运输条件

Room temperature in continental US; may vary elsewhere.

储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 2 years
-20°C 1 year
溶解性数据
细胞实验: 

DMSO 中的溶解度 : 25 mg/mL (60.32 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 2.4126 mL 12.0630 mL 24.1260 mL
5 mM 0.4825 mL 2.4126 mL 4.8252 mL
查看完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 2 years; -20°C, 1 year。-80°C储存时,请在2年内使用, -20°C储存时,请在1年内使用。

  • 摩尔计算器

  • 稀释计算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

质量
=
浓度
×
体积
×
分子量 *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

浓度 (start)

C1

×
体积 (start)

V1

=
浓度 (final)

C2

×
体积 (final)

V2

动物实验:

请根据您的 实验动物和给药方式 选择适当的溶解方案。

以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:
——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用
以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 方案 一

    请依序添加每种溶剂: 10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.5 mg/mL (6.03 mM); 澄清溶液

    此方案可获得 ≥ 2.5 mg/mL(饱和度未知)的澄清溶液。

    1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;再向上述体系中加入 50 μL Tween-80,混合均匀;然后再继续加入 450 μL 生理盐水 定容至 1 mL

    生理盐水的配制:将 0.9 g 氯化钠,溶解于 ddH₂O 并定容至 100 mL,可以得到澄清透明的生理盐水溶液。
  • 方案 二

    请依序添加每种溶剂: 10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 2.5 mg/mL (6.03 mM); 澄清溶液

    此方案可获得 ≥ 2.5 mg/mL(饱和度未知)的澄清溶液。

    1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液 中,混合均匀。

    2 g SBE-β-CD(磺丁基醚 β-环糊精)粉末定容于 10 mL 的生理盐水中,完全溶解至澄清透明。
动物溶解方案计算器
请输入动物实验的基本信息:

给药剂量

mg/kg

动物的平均体重

g

每只动物的给药体积

μL

动物数量

由于实验过程有损耗,建议您多配一只动物的量
请输入您的动物体内配方组成:
%
DMSO +
+
%
Tween-80 +
%
Saline
如果您的动物是免疫缺陷鼠或者体弱鼠,建议 DMSO 中的在最后工作液体系中的占比尽量不超过 2%。
方案所需 助溶剂 包括:DMSO ,均可在 MCE 网站选购。 Tween 80,均可在 MCE 网站选购。
计算结果
工作液所需浓度 : mg/mL
储备液配制方法 : mg 药物溶于 μL  DMSO(母液浓度为 mg/mL)。
您所需的储备液浓度超过该产品的实测溶解度,以下方案仅供参考,如有需要,请与 MCE 中国技术支持联系。
动物实验体内工作液的配制方法 : 取 μL DMSO 储备液,加入 μL  μL ,混合均匀至澄清,再加 μL Tween 80,混合均匀至澄清,再加 μL 生理盐水
连续给药周期超过半月以上,请谨慎选择该方案。
请确保第一步储备液溶解至澄清状态,从左到右依次添加助溶剂。您可采用超声加热 (超声清洗仪,建议频次 20-40 kHz),涡旋吹打等方式辅助溶解。
纯度 & 产品资料

纯度: 99.81%

参考文献

完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 2 years; -20°C, 1 year。-80°C储存时,请在2年内使用, -20°C储存时,请在1年内使用。

可选溶剂 浓度 溶剂体积 质量 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 2.4126 mL 12.0630 mL 24.1260 mL 60.3151 mL
5 mM 0.4825 mL 2.4126 mL 4.8252 mL 12.0630 mL
10 mM 0.2413 mL 1.2063 mL 2.4126 mL 6.0315 mL
15 mM 0.1608 mL 0.8042 mL 1.6084 mL 4.0210 mL
20 mM 0.1206 mL 0.6032 mL 1.2063 mL 3.0158 mL
25 mM 0.0965 mL 0.4825 mL 0.9650 mL 2.4126 mL
30 mM 0.0804 mL 0.4021 mL 0.8042 mL 2.0105 mL
40 mM 0.0603 mL 0.3016 mL 0.6032 mL 1.5079 mL
50 mM 0.0483 mL 0.2413 mL 0.4825 mL 1.2063 mL
60 mM 0.0402 mL 0.2011 mL 0.4021 mL 1.0053 mL
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

您最近查看的产品:

Your information is safe with us. * Required Fields.

   产品名称:

 

* 需求量:

* 客户姓名:

 

* Email:

* 电话:

 

* 公司或机构名称:

   留言给我们:

Bulk Inquiry

Inquiry Information

产品名称:
Eplerenone
目录号:
HY-B0251
需求量: